A phase I, pharmacokinetic, dosage escalation study of creatine monohydrate in subjects with amyotrophic lateral sclerosis
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Nazem Atassi*a, Eva-Maria Rataia, David J. Greenblattb, Darlene Pulleya, Yanli Zhaob, Jeffery Bombardiera, Stuart Wallacea, Joanna Eckenrodea, Merit Cudkowicza & Allitia Dibernardoaa Massachusetts General Hospitalb Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine and Tufts Medical Center, Boston, USACorrespondence: N. Atassi, Massachusetts General Hospital, Neurology Clinical Trials Unit (NCTU), 13th Street, Building 149, Room 2274, Charlestown, Massachusetts 02129, USA. Fax: 617 7247290. E-mail: NATASSI@PARTNERS.ORGAbstractCreatine monohydrate (creatine) has potential neuroprotective properties and is a commonly used supplement in amyotrophic lateral sclerosis (ALS) and other neurodegenerative disorders. Minimum therapeutic and maximum tolerated dosages of creatine are not yet known, nor is it known what systemic plasma concentrations result from specific dosage regimens. The objectives of this study were to establish steady-state plasma pharmacokinetics of creatine at several dosages, and to evaluate the effects of creatine on brain metabolites using proton magnetic resonance spectroscopy (1H-MRS). Six participants with ALS received creatine at three weekly escalating oral dosages (5, 10, and 15 g b.i.d.). Plasma creatine levels and MR spectra were obtained at baseline and with each dosage increase. Mean pre-dose steady-state creatine plasma concentrations were 20.3, 39.3, and 61.5 ug/ml at 5, 10, and 15 g b.i.d., respectively. Creatine spectra increased by 8% (p = 0.06) and glutamate + glutamine signals decreased by 17% (p = 0.039) at higher dosages. There were no safety concerns at any of the dosages. In conclusion, creatine plasma concentrations increased in a dose-dependent manner. Creatine appears to cross the blood-brain barrier, and oral administration of 15 g b.i.d. is associated with increased in vivo brain creatine concentrations and decreased glutamate concentrations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuroprotective Effects of Creatine in a Transgenic Mouse Model of Huntington's Disease
Ferrante, R. J., Andreassen, O. A., Jenkins, B. G., Dedeoglu, A., Kuemmerle, S., Kubilus, J. K., Kaddurah-Daouk, R., Hersch, S. M., & Beal, M. F. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-12-04389.2000 · Cited by 522
Direct antioxidant properties of creatine
Lawler, J. M., Barnes, W. S., Wu, G., Song, W., & Demaree, S. (2002) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.6164 · Cited by 448 · cited 1×
“Creatine, an endogenously synthesized amino acid, has been shown to stabilize the mitochondrial transition pore (2), buffer intracellular energy stores (3), stimulate synaptic glutamate uptake (4), and scavenge reactive oxygen species (5).”
BackgroundDedeoglu, A., Kubilus, J. K., Yang, L., Ferrante, K. L., Hersch, S. M., Beal, M. F., & Ferrante, A. R. J. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01706.x · Cited by 169 · cited 1×
“Preclinical evidence suggests that supplementing creatine is neuroprotective in vivo in animal models of neurodegenerative disease states and that the effects are dose dependent (6-9).”
BackgroundPharmacokinetics of the Dietary Supplement Creatine
Persky, A. M., Brazeau, G. A., & Hochhaus, G. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342060-00005 · Cited by 132 · cited 1×
“Creatine represents an unusually compelling candidate within this class due to the strength of its preclinical data, emerging clinical evidence in other neurodegenerative diseases, and its known tolerability at a range of dosages (24).”
Background
Cited by
Cook, C. J., Crewther, B. T., Kilduff, L. P., Drawer, S., & Gaviglio, C. M. (2011) · Journal of the International Society of Sports Nutrition · doi:10.1186/1550-2783-8-2 · Cited by 104
“Creatine supplementation has been shown to improve certain aspects of cognitive performance with sleep deprivation and to have some positive benefits in deficits associated with certain pathophysiologies [13,14].”
InfluentialCreatine for neuroprotection in neurodegenerative disease: end of story?
Bender, A., & Klopstock, T. (2016) · Amino Acids · doi:10.1007/s00726-015-2165-0 · Cited by 96
“…with 30 g of Cr/day may also be reflected by the fact that in the typical mouse studies, brain Cr increased by 21 ± 3.8 % while in the human randomized trials, only increases between 7.5 and 13 % could be obtained (Ferrante et al. 2000; Atassi et al. 2010; Hersch et al. 2006; Lyoo et al. 2003).”
BackgroundInfluentialKondo, D. G., Forrest, L. N., Shi, X., Sung, Y.-H., Hellem, T. L., Huber, R. S., & Renshaw, P. F. (2016) · Amino Acids · doi:10.1007/s00726-016-2194-3 · Cited by 79
de Guingand, D. L., Palmer, K. R., Snow, R. J., Davies-Tuck, M. L., & Ellery, S. J. (2020) · Nutrients · doi:10.3390/nu12061780 · Cited by 35
Absolute Oral Bioavailability of Creatine Monohydrate in Rats: Debunking a Myth
Alraddadi, E., Lillico, R., Vennerstrom, J., Lakowski, T., & Miller, D. (2018) · Pharmaceutics · doi:10.3390/pharmaceutics10010031 · Cited by 30
Metadata
- Authors
- Atassi, N., Ratai, E.-M., Greenblatt, D. J., Pulley, D., Zhao, Y., Bombardier, J., Wallace, S., Eckenrode, J., Cudkowicz, M., & Dibernardo, A.
- Venue
- Amyotrophic Lateral Sclerosis
- Publisher
- Informa UK Limited
- Published
- 2010-08-11
- Volume
- 11
- Issue
- 6
- Pages
- 508-513
- ISSN
- 1471-180X (ISSN-L)
- 1748-2968
- OpenAlex
- W1972633070
- Cited by
- 37
- References
- 4
- FWCI
- 2.08
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A phase I, pharmacokinetic, dosage escalation study of creatine monohydrate in subjects with amyotrophic lateral sclerosis. https://app.cochat.ai/papers/10.3109/17482961003797130
- The paper
- Atassi, N., Ratai, E.-M., Greenblatt, D. J., Pulley, D., Zhao, Y., Bombardier, J., Wallace, S., Eckenrode, J., Cudkowicz, M., & Dibernardo, A. (2010). A phase I, pharmacokinetic, dosage escalation study of creatine monohydrate in subjects with amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis. https://doi.org/10.3109/17482961003797130
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.